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Abstract
Tyrosinemia Type 1 is a rare inherited metabolic disorder attributable to a deficiency of enzyme fumarylacetoacetate hydrolase. It has 
an autosomal recessive pattern of inheritance. The accumulation of tyrosine and its toxic metabolites succinylacetone and succinyl 
acetoacetate in various tissues leads to the characteristic hepatic failure, renal dysfunction, and neurological crisis. Here, we present a 
case of a 7-month-old female infant who was brought with complaints of jaundice, dyspnea, altered level of consciousness, refusal to 
feed. We highlight the need for early diagnosis, including prenatal testing and initiating treatment at the earliest, which goes a long way 
not only in the survival, but also the quality of life in these patients.
Key words:  Inborn error of metabolism, Neonatal hyperbilirubinemia, NTBC therapy, Prenatal diagnosis, Tyrosinemia 
Tyrosinemia Type 1 is an autosomal recessive inborn error of amino acid, tyrosine metabolism. The enzyme deficient is fumarylacetoacetate hydrolase 
(FAH) coded by FAH gene that is located on chromosome 
15q25.1 [1,2]. The altered FAH gene produces an unstable 
or inactive enzyme, which results in reduced or absent FAH 
activity, which in turn results in accumulation of fumaryl- and 
maleyl-acetoacetate causing cellular damage. Fumaryl- and 
maleyl-acetoacetate are reactive compounds and have not 
been identified in tyrosinemia patients. Succinylacetone, 
however, is derived from these metabolites by reduction and 
decarboxylation, is elevated in serum and urine from the 
patients.
Tyrosinemia is clinically heterogeneous. Symptoms may 
start during the first few months (acute type), in the second 
half of the 1st year (sub-acute type) or in the following years up 
to adulthood (chronic type). In the acute type, manifestations 
of hepatic failure predominate. Children older than 6 months 
of age present with signs of renal disease, rickets, and/or 
neurologic crisis, which include change in mental status. 
Abdominal pain, peripheral neuropathy, and seizures may 
compound the illness at any stage. Those children who are 
not treated with nitisinone and a low-tyrosine diet and who 
survive the acute onset of liver failure are at high risk of 
developing hepatocellular carcinoma [3]. The effective 
therapeutic use of 2-(2-nitro-4-trifluoromethylbenzoyl)-
1,3-cyclohexanedione (NTBC) in tyrosinemia prevents the 
accumulation of fumarylacetoacetate and its conversion to 
succinylacetone.
CASE REPORT
A 7-month-old female infant brought with fever, difficulty 
breathing, associated with chest in drawing, grunting and 
mouth breathing for 4 days. The baby was lethargic and 
drowsy and refusing to feed for 3 days. There was a history of 
decreased urine output since 2 days. She was the 5th offspring 
born to 2nd degree consanguineous couple, after an uneventful 
pregnancy. She had complaints of yellowish discoloration 
of skin and eyes since 1 month of age and also distension of 
abdomen since the last 4 months, which was slowly progressive 
and accompanied with frequent episodes of vomiting following 
feeds. She was admitted previously for 15 days at 6 months 
of the age for similar complaints. The mother had noticed the 
infant and its urine to be having a distinct odor similar to that of 
boiled cabbage. However, there was no history of convulsions, 
blood in stool or vomitus, nose bleeds or cyanosis. The child 
attained developmental milestones at the appropriate age 
except that it finds difficult to go prone due to the distended 
abdomen. The couple had lost a son to similar complaints at the 
age of 6 months. Child was fully immunized for date.
On physical examination, the patient appeared sick, icteric, 
febrile and drowsy. There was marked pallor and respiratory 
distress. The patient weighed 5.3 kg (66.25% of normal weight 
for age) and the anterior fontanelle was 3 cm × 3 cm wide. 
Examination of the abdomen revealed distended abdomen, 
everted umbilicus, liver was barely palpable below the right 
costal margin, spleen was palpable 3 cm below the left costal 
margin. Fluid thrill was present. Chest examination showed 
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in-drawing of chest, hurried breathing, wheeze audible close 
to the chest wall, apex beat in the 5th intercostal space on the 
left side at midclavicular line. The chest expansion was barely 
1-1.5 cm. On auscultation, bronchial breath sounds heard, 
associated with widespread rhonchi. Heart sounds were normal 
without any added sounds. Examination of central nervous 
system revealed a drowsy infant responding only to painful 
stimuli, not interested in surroundings or play. Rest of the 
nervous system examination was unremarkable.
Her hemoglobin was 9.8 g/dl and leukocyte counts were raised 
(18,100/mm3) with normal platelet counts. Peripheral smear 
examination showed normocytic normochromic anemia with 
leukocytosis. Blood urea and serum creatinine were markedly 
elevated (56.6 and 2.8 mg/dl respectively). Liver function test 
revealed conjugated hyperbilirubinemia (total bilirubin - 35.5, 
direct - 29.6 and indirect bilirubin - 5.9 mg/dl). Hepatic 
enzymes were also elevated (aspartate aminotransferase – 
198 U/L, alanine aminotransferase – 99 U/L, alkaline 
phosphatse - 625.1 IU/L). Prothrombin time (PT) was 27 s 
(control 15 s) and partial thromboplastin time (PTT) was 
67.3 s (control 30 s). Ultrasonography of the abdomen showed 
contracted gall bladder, and moderate spleenomegaly features 
suggestive of obstructive jaundice.
The patient was put on 3 consecutive days of intramuscular 
injection of vitamin K; however, the prolonged PT and PTT 
were unresponsive and incompatible with liver function tests. 
Despite the grossly deranged coagulation profile, the patient 
had no history of bleeding tendency. Therefore, metabolic 
causes for acute liver failure were considered. Serum alpha-
fetoprotein (AFP) level was extremely high >363,000 ng/ml 
(normal <9 ng/ml). Her tandem mass spectrometry revealed 
elevated tyrosine levels (Table 1).
In the light of these findings, the infant was diagnosed to 
have tyrosinemia Type 1. The patient was referred to our tertiary 
care from a peripheral center. Lack of awareness on the part of 
the parents to seek timely medical advice, delay in referral to 
a higher center caused a time lag in enrolling the patient on 
NTBC therapy. The prospect of liver transplantation was also 
considered. With the delay in diagnosis and to institute specific 
treatment and the feasibility of pediatric liver transplant being 
so bleak in our country, the patient, unfortunately, succumbed 
to the illness.
DISCUSSION
Tyrosinemia is an inborn error of tyrosine metabolism. It 
is of three distinct types. Tyrosinemia Type 1 is due to the 
deficiency of the enzyme FAH. Worldwide, Type I tyrosinemia 
affects about one person in 100,000. This is more common 
in the Saguenay-Lac St. Jean region of Quebec, it affects one 
person in 1846 [4]. Tyrosinemia I is an autosomal recessive 
disorder; therefore, the sex distribution is equal [5]. Type 2, 
Reichner Hanhart syndrome, is caused by a deficiency 
of tyrosine aminotransferase enzyme which leads to the 
characteristic occulocutaneous syndrome. Type 3 Tyrosinemia 
is due to deficiency of 4-hydroxypyruvate dioxygenase enzyme 
characterized by mental and motor retardation, seizures and 
intermittent ataxia [6].
Tyrosinemia type 1 is an inborn error of tyrosine catabolism 
characterized by progressive liver disease, renal tubular 
dysfunction, neurological crises and a dramatic improvement in 
prognosis following treatment with nitisinone. These changes 
are brought about by the deposition of amino acids such as 
tyrosine, methionine and toxic byproducts of amino acid 
metabolism like succinylacetone and succinylacetatoactetate. 
The diagnosis of tyrosinemia can be established by 
determination of succinylacetone in urine or serum and by 
assay of FAH activity in lymphocytes and fibroblasts [7]. The 
elevated levels of serum tyrosine and methionine provided key 
for the diagnosis in our patient, further strengthened by the 
deranged liver function parameters, and abnormal coagulation 
profile. Though, the infant was given a provisional diagnosis 
of neonatal hepatitis, the alarmingly high levels of AFP were 
indicative of intrauterine liver damage. AFP is elevated in 
certain conditions like the omphalocele, viral hepatitis, neonatal 
iron storage disorders, hepatocellular carcinoma, extrahepatic 
biliary atresia [8].
Prenatal diagnosis of tyrosinemia is possible by analysis 
of succinylacetone in amniotic fluid supernatant and by assay 
of FAH in cultured amniotic fluid cells or a chorionic villus 
material [9]. Any infant who is jaundiced at 2-4 weeks old, 
even if he looks otherwise well should undergo methodical 
and comprehensive diagnostic investigations. Differential 
diagnoses include neonatal hemochromatosis, classic 
galactosemia, hereditary fructosemia, and citrullinemia 
type 2 which can be ruled out by investigations as listed in 
Table 2.
Table 1: Screening for inborn errors of metabolism by 
tandem mass spectrometry
Amino acid Test Normal range
Tyrosine 528.68 µmol/L 17-250 µmol/L
Methionine 51.82 µmol/L 1-44 µmol/L
Phenylalanine 32.16 µmol/L 21-136 µmol/
Citrulline 32.16 µmol/L 0-45 µmol/L
Table 2: Differential diagnoses for tyrosinemia Type I
Neonatal 
hemochromatosis
Elevated transferrin saturation 
and serum ferritin levels
Classic Galactosemia Quantitative erythrocyte 
galactose-1-phosphate 
uridyltransferase analysis
Hereditary fructosemia Enzyme analysis, genetic testing
Citrullinemia Type 2 Tandem mass spectrometry
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Although, it greatly slows the progression of the disease, 
permanent liver damage is inevitable [10]. Osteoporosis 
and rickets resulting from renal tubular damage are treated 
by correction of acidosis, restoring calcium and phosphate 
balance, and administration of 25-hydroxy-vitamin D. Liver 
transplantation is the treatment of last resort when patients 
fail to respond To NTBC therapy or develop hepatocellular 
cancer. Early nitisinone treatment reduces the need for liver 
transplantation in children with tyrosinemia Type 1 and for 
those progressing to liver transplantation despite use of NTBC 
results in improved post-transplant renal function.
CONCLUSION
When there is a positive family history known as seen in our 
case report, prenatal testing can be used to clarify the genetic 
status of at-risk sibling before birth. As clinicians, we need to 
look beyond infections and consider the possibility of other 
rarer causes that often go undiagnosed.
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